IGLV1-62: A Potential Drug Target and Biomarker (G28819)

Target Name: IGLV1-62

NCBI ID: G28819

IGLV1-62

Other Name(s): IGLV162 | Immunoglobulin lambda variable 1-62 (pseudogene) | V1-23P | immunoglobulin lambda variable 1-62 (pseudogene)

IGLV1-62: A Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers is a crucial step in the development of new pharmaceuticals. IGLV1-62 is a protein that has been identified as a potential drug target and biomarker. In this article, we will explore IGLV1-62 and its potential as a drug target and biomarker.

IGLV1-62: A Protein with Multiple Functions

IGLV1-62 (Interleukin-62) is a cytokine that is expressed in various tissues and cells in the body. It has been shown to play a role in the regulation of immune responses, inflammation, and cellular signaling. IGLV1-62 has also been shown to have multiple functions, including the regulation of cell adhesion, the production of antibodies, and the regulation of cellular signaling pathways.

One of the most promising aspects of IGLV1-62 is its potential as a drug target. IGLV1-62 has been shown to interact with several protein targets, including the T-cell receptor (TCR), the B-cell receptor (BCR), and the intercellular adhesion molecule (ICAM). These interactions suggest that IGLV1-62 may be a useful target for new pharmaceuticals.

IGLV1-62 as a Biomarker

IGLV1-62 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, IGLV1-62 has been shown to be upregulated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that IGLV1-62 may be a useful biomarker for these diseases and may help to identify new targets for cancer therapies.

IGLV1-62 has also been shown to be upregulated in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that IGLV1-62 may be a useful biomarker for these diseases and may help to identify new targets for neurodegenerative therapies.

IGLV1-62 has also been shown to be upregulated in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. This suggests that IGLV1-62 may be a useful biomarker for these diseases and may help to identify new targets for autoimmune therapies.

Conclusion

IGLV1-62 is a protein that has been shown to play a role in the regulation of immune responses, inflammation, and cellular signaling. Its multiple functions make it a promising target for new pharmaceuticals. IGLV1-62 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the potential of IGLV1-62 as a drug target and biomarker.

Protein Name: Immunoglobulin Lambda Variable 1-62 (pseudogene)

The "IGLV1-62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV1-62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets